Publications by authors named "Warren Mason"

100Publications

Proteasome inhibition for the treatment of glioblastoma.

Expert Opin Investig Drugs 2020 Oct 10;29(10):1133-1141. Epub 2020 Aug 10.

Department of Neurology, Brain Tumor Center and Comprehensive Cancer Center Zurich, University Hospital and University of Zurich , Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2020.1803827DOI Listing
October 2020

Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients.

J Neurooncol 2020 Aug 6;149(1):65-71. Epub 2020 Jul 6.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 610 University Ave, Toronto, ON, M5G2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-020-03573-xDOI Listing
August 2020

Guillain-Barré Syndrome following a series of novel therapies adapting the gold-standard in the era of immune priming.

J Neuroimmunol 2020 May 21;346:577267. Epub 2020 May 21.

Department of Medical Oncology, Immune Therapy Program, University Health Network, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jneuroim.2020.577267DOI Listing
May 2020

Glioblastoma Spinal Cord Metastasis With Short-Term Clinical Improvement After Radiation.

Can J Neurol Sci 2020 Jun 11:1-3. Epub 2020 Jun 11.

Princess Margaret Cancer Centre, Department of Medical Oncology, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/cjn.2020.122DOI Listing
June 2020

Molecular Classification of Diffuse Gliomas.

Can J Neurol Sci 2020 07 10;47(4):464-473. Epub 2020 Jan 10.

Department of Medical Oncology and Hematology, University Health Network, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/cjn.2020.10DOI Listing
July 2020

Cognitive rehabilitation for executive dysfunction in brain tumor patients: a pilot randomized controlled trial.

J Neurooncol 2019 May 7;142(3):565-575. Epub 2019 Mar 7.

Department of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-019-03130-1DOI Listing
May 2019

Tissue 2-Hydroxyglutarate as a Biomarker for Mutations in Gliomas.

Clin Cancer Res 2019 06 18;25(11):3366-3373. Epub 2019 Feb 18.

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-3205DOI Listing
June 2019

Significance of treatment response when managing patients with primary central nervous system lymphoma.

Leuk Lymphoma 2019 02 3;60(2):349-357. Epub 2018 Jul 3.

d Princess Margaret Hospital and Mt. Sinai Hospital, University of Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1474524DOI Listing
February 2019

mTOR inhibition in glioblastoma: requiem for a dream?

Neuro Oncol 2018 04;20(5):584-585

Department of Medicine, Princess Margaret Cancer Centre and University of Toronto.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy034DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892149PMC
April 2018

Oculoleptomeningeal Amyloidosis Secondary to the Rare Transthyretin c.381T>G (p.Ile127Met) Mutation.

World Neurosurg 2018 Mar 23;111:190-193. Epub 2017 Dec 23.

Division of Neurosurgery, University Health Network, University of Toronto, Toronto, Ontario, Canada. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S18788750173221
Publisher Site
http://dx.doi.org/10.1016/j.wneu.2017.12.096DOI Listing
March 2018

Management and Outcomes in the Oldest-Old Population with Glioblastoma.

Can J Neurol Sci 2018 03 18;45(2):199-205. Epub 2017 Dec 18.

1Department of Radiation Oncology,University of Toronto,Princess Margaret Hospital,Toronto,Ontario,Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/cjn.2017.278DOI Listing
March 2018

Contemporary management of high-grade gliomas.

CNS Oncol 2018 01 15;7(1):51-65. Epub 2017 Dec 15.

Princess Margaret Cancer Centre, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/cns-2017-0026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001673PMC
January 2018

Bevacizumab in Recurrent High-Grade Gliomas: A Canadian Retrospective Study.

Can J Neurol Sci 2018 01 20;45(1):56-61. Epub 2017 Nov 20.

1Department of Medicine,Division of Neurology,University of Toronto,Toronto,Ontario,Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/cjn.2017.248DOI Listing
January 2018

What are the prospects for combination therapy for glioblastoma?

Expert Rev Neurother 2017 10 12;17(10):947-949. Epub 2017 Jul 12.

a Princess Margaret Hospital Cancer Centre.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2017.1351300DOI Listing
October 2017

Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma.

Neuro Oncol 2017 Oct;19(11):1542-1552

Pediatric Neuro-Oncology, Dana-Farber Boston Children's Cancer Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA; The Royal Marsden Hospital, Sutton, Surrey, UK; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Medical Oncology, Azienda USL-IRCCS Institute of Neurological Science, Bologna, Italy; Institut Curie and University Paris Descartes, Paris, France; Division of Haematology/Oncology at The Hospital for Sick Children, Toronto, Ontario, Canada; Sir James Spence Institute of Child Health Royal Victoria Infirmary, Newcastle, UK; Seattle Children's Hospital, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington, USA; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia, USA; The Royal Children's Hospital, Children's Cancer Center, Melbourne, Australia; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA; Catholic University of the Sacred Heart, Rome, Italy; Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Paediatric Oncology Unit, Great Ormond Street Hospital, London, UK; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA; Gustave Roussy, Department of Pediatric and Adolescent Oncology, University Paris-Sud, Université Paris-Saclay, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nox109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5737275PMC
October 2017

Radiation plus Temozolomide in Patients with Glioblastoma.

N Engl J Med 2017 06;376(22):2197

University of Toronto, Toronto, ON, Canada

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1704726DOI Listing
June 2017

NANO, a practical scale for neurologic assessments in patients with brain tumors?

Authors:
Warren Mason

Neuro Oncol 2017 05;19(5):603-604

Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nox048DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464456PMC
May 2017

Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.

Neuro Oncol 2017 Aug;19(8):1119-1126

Tel-Aviv Sourasky Medical Center, Tel-Aviv University; European Organization for Research and Treatment of Cancer, Brussels (EORTC); National Institutes of Health (M.R.M.); University of Alabama at Birmingham; Princess Margaret Cancer Centre, University of Toronto; Lausanne University Hospital; NRG Oncology Statistics and Data Management Center; Odette Cancer Centre and Sunnybrook Health Sciences Centre, University of Toronto; Samsung Medical Center, Sungkyunkwan University School of Medicine; Edinburgh Cancer Centre; Mayo Clinic; Robert-Janker Clinic at the University of Bonn Medical Centre, and MAASTRO clinic, GROW School for Oncology, Maastricht University Medical Centre; Miami Cancer Institute; Erasmus University Hospital; Dana-Farber Cancer Institute and Harvard Medical School; University of Zurich.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nox025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570239PMC
August 2017

Neutrophil-lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival.

J Neurooncol 2017 05 22;132(3):463-471. Epub 2017 Mar 22.

Department of Radiation Oncology, University Health Network-Princess Margaret Cancer Centre/University of Toronto, 610 University Ave., Toronto, ON, M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-017-2395-yDOI Listing
May 2017

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.

N Engl J Med 2017 03;376(11):1027-1037

From Odette Cancer Centre, Sunnybrook Health Sciences Centre (J.R.P., A.S.) and Princess Margaret Cancer Centre (N.L., W.P.M.), Toronto, the Canadian Cancer Trials Group, Queens University, Kingston, ON (C.J.O., C.W., K.D.), University of Calgary, Calgary, AB (J.G.C.), University of Alberta, Edmonton (W.R.), Quality of Life Consulting, West Vancouver, BC (D.O.), Queen's University, Kingston General Hospital, Kingston, ON (J.P.R.), and Juravinski Cancer Centre, Hamilton, ON (H.H.) - all in Canada; Azienda Unità Sanitaria Locale- Istituto di Ricovero e Cura a Carattere Scientifico Istituto delle Scienze Neurologiche, Bologna (A.A.B., E.F.), and Fondazione Istituto Neurologico Carlo Besta, Milan (L. Fariselli) - both in Italy; University Hospital Gasthuisberg, Leuven, Belgium (J.M.); Peter MacCallum Cancer Centre, Melbourne, VIC (C.P.), University of Newcastle, Newcastle, NSW (M.F.), University of Queensland, Brisbane (M.F.), and Royal North Shore Hospital, Sydney (M.B.) - all in Australia; Saitama Medical University International Medical Center, Saitama, Japan (R.N.); Hôpital de la Pitié-Salpêtrière (F.L.-D., L. Feuvret), Paris, and Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Centre Hospitalier Universitaire Timone, Marseilles (O.C.) - both in France; the European Organization for Research and Treatment of Cancer, Brussels (V.G.); the Neurology Clinic, University of Heidelberg, Heidelberg, Germany (A.W., W.W.); Tauranga Hospital, Tauranga, New Zealand (M.T.); and Maastricht University Medical Center and School for Oncology and Developmental Biology, Maastricht, the Netherlands (B.G.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1611977DOI Listing
March 2017

Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

Lancet Oncol 2016 Nov 27;17(11):1533-1542. Epub 2016 Sep 27.

Department of Medical Oncology and Cancer Centre, University Hospital Zurich, Zurich, Switzerland; Department of Radiation-Oncology (MAASTRO), Maastricht University Medical Centre (MUMC) and GROW (School for Oncology), Maastricht, Netherlands; Department of Radiation-Oncology, MediClin Robert-Janker-Clinic, Clinical Cooperation Unit Neuro-oncology, University Bonn Medical Centre, Bonn, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30305-9DOI Listing
November 2016

Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.

Neuro Oncol 2017 01 31;19(1):89-98. Epub 2016 Aug 31.

UCLA Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (B.M.E., R.J.H., D.C.W., K.L., O.Z.); Dept. of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (B.M.E., R.J.H., D.C.W., K.L., O.Z., W.B.P.); Dept. of Physics and Biology in Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (B.M.E.); Dept. of Medicine, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada (W.P.M.);H. Lee Moffitt Cancer Center, Tampa, Florida (S.S.); F. Hoffman-La Roche, Ltd., Basel, Switzerland (L.E.A.); Exelixis, South San Francisco, California (D.T.A., G.M.S., C.H.); Dept. of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (A.L., P.L.N., T.F.C.); Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (P.Y.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now187DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5193027PMC
January 2017

Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.

Neuro Oncol 2016 10 11;18(10):1434-41. Epub 2016 Aug 11.

University Medical Center, Heidelberg, Germany (W.W., M.B.); Aix-Marseille University, AP-HM, Service de Neuro-Oncologie, CHU Timone, Marseille, France (O.L.C.); Princess Margaret Hospital, * Toronto, Canada (W.M.); Regional Cancer Center Stockholm Gotland, Stockholm, Sweden (R.H.); Department of Radiation Sciences and Oncology, Umeå University, Umeå, Sweden (R.H.); The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK (F.S.); Saitama Medical University, Iruma, Saitama Prefecture, Japan (R.N.); F. Hoffmann-La Roche Ltd, Basel, Switzerland (C.R., Y.K.); University of California Los Angeles, Los Angeles, California (T.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now091DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035525PMC
October 2016

Assessing behavioral syndromes in patients with brain tumors using the frontal systems behavior scale (FrSBe).

Neurooncol Pract 2016 Jun 24;3(2):113-119. Epub 2015 Nov 24.

Memory Clinic, Toronto Western Hospital, 399 Bathurst St, Toronto M5T 2S8, Canada (S.C., M.C.T.); Pencer Brain Tumor Centre, Princess Margaret Cancer Centre, 610 University Ave, Toronto M5G 2M9, Canada (S.C., K.E., W.P.M.); Department of Psychosocial Oncology & Palliative Care, Princess Margaret Cancer Centre, 610 University Ave, Toronto M5G 2M9, Canada (K.E.); Department of Hematology Oncology, Princess Margaret Cancer Centre, 610 University Ave, Toronto M5G 2M9, Canada (S.C., W.P.M.); Department of Neurology, University of Toronto, Toronto, Canada (S.C., W.P.M., M.C.T.); Department of Psychiatry, University of Toronto, Toronto, Canada (K.E.); Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, Canada (M.C.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/nop/npv055DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668266PMC
June 2016

A critical balance: managing coagulation in patients with glioma.

Expert Rev Neurother 2016 07 9;16(7):803-14. Epub 2016 May 9.

a Pencer Brain Tumor Centre , Princess Margaret Hospital Cancer Centre , Toronto , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2016.1181542DOI Listing
July 2016

Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.

Neuro Oncol 2016 09 22;18(9):1313-8. Epub 2016 Mar 22.

Aix-Marseille University, AP-HM, Service de Neuro-Oncologie, CHU Timone, Marseille, France (O.L.C.); Saitama Medical University, Saitama, Japan (R.N.); Princess Margaret Hospital, Toronto, Canada (W.M.); Regional Cancer Center Stockholm Gotland, Stockholm, Sweden (R.H.); Department of Radiation Sciences and Oncology, Umeå University, Umeå, Sweden (R.H.); The Royal Marsden NHS Foundation Trust, Surrey, UK (F.S.); University of California, Los Angeles, California, USA (T.C.); F. Hoffmann-La Roche Ltd, Basel, Switzerland (J.G., C.R., L.A.); University Medical Center, Heidelberg, Germany (W.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now046DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4999000PMC
September 2016

Reply to T.J. Kruser et al.

J Clin Oncol 2016 Apr 16;34(11):1282-3. Epub 2016 Feb 16.

University of California, Los Angeles, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.2438DOI Listing
April 2016

Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy.

Neuro Oncol 2016 07 24;18(7):991-1001. Epub 2016 Jan 24.

The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK (F.S.); Aix-Marseille University, AP-HM, Service de Neuro-Oncologie, CHU Timone, Marseille, France (O.L.C.); Regional Cancer Center, Stockholm-Gotland, Karolinska University Hospital, Stockholm, Sweden (R.H.); Department of Radiation Sciences and Oncology, Umeå University, Förvaltningshuset, Universitetstorget, Umeå, Sweden (R.H.); Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario, Canada (W.M.); University Medical Center and German Cancer Research Center, Heidelberg, Germany (W.W.); University of California, Los Angeles, California, USA (T.C.); Genentech Inc., South San Francisco, California, USA (S.D.); F. Hoffmann-La Roche Ltd, Basel, Switzerland (E.P., J.G.); Saitama Medical University, Saitama, Japan (R.N.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov300DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4896538PMC
July 2016

Neurosurgical management of adult diffuse low grade gliomas in Canada: a multi-center survey.

J Neurooncol 2016 Jan 10;126(1):137-149. Epub 2015 Oct 10.

Division of Neurosurgery, University Health Network, Toronto Western Hospital, University of Toronto, 399 Bathurst Street, Toronto, ON, M5T 2S8, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-015-1949-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4683163PMC
January 2016

Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma.

Cancer Immunol Res 2015 Dec 29;3(12):1299-302. Epub 2015 Sep 29.

Princess Margaret Cancer Centre, University Health Network Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0141DOI Listing
December 2015

Illness intrusiveness and subjective well-being in patients with glioblastoma.

J Neurooncol 2016 Jan 29;126(1):127-135. Epub 2015 Sep 29.

Psychosocial Oncology & Palliative Care, Princess Margaret Cancer Centre, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-015-1943-6DOI Listing
January 2016

Blood-brain barrier-associated efflux transporters: a significant but underappreciated obstacle to drug development in glioblastoma.

Authors:
Warren P Mason

Neuro Oncol 2015 Sep 1;17(9):1181-2. Epub 2015 Jul 1.

Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada (W.P.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov122DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588763PMC
September 2015

Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.

J Clin Oncol 2015 Sep 29;33(25):2735-44. Epub 2015 Jun 29.

Thomas Sandmann, Richard Bourgon, Congfen Li, Samir Kharbanda, Franklin Peale, Priti Hegde, Heidi S. Phillips, and Carlos Bais, Genentech, South San Francisco; Timothy Cloughesy and Albert Lai, University of California Los Angeles, Los Angeles, CA; Josep Garcia, Nicola Moore, and Lauren E. Abrey F. Hoffmann-La Roche, Basel, Switzerland; Olivier L. Chinot, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Centre Hospitalier Universitaire Timone, Marseille, France; Wolfgang Wick, University Medical Center, Heidelberg, Germany; Ryo Nishikawa, Saitama Medical University, Saitama, Japan; Warren Mason, Princess Margaret Hospital, Toronto, Ontario, Canada; Roger Henriksson, Regional Cancer Center Stockholm, Stockholm; and Umeå University, Umeå, Sweden; and Frank Saran, Royal Marsden National Health Service Foundation Trust, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.61.5005
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.61.5005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015426PMC
September 2015

Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide.

J Neurooncol 2015 Aug 27;124(1):119-26. Epub 2015 May 27.

Department of Radiation Oncology, University of Toronto/ University Health Network-Princess Margaret Cancer Centre, 610 University Ave, Toronto, ON, M5T 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-015-1815-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498235PMC
August 2015

Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.

J Clin Oncol 2015 Jul 26;33(19):2166-75. Epub 2015 May 26.

Martin J.B. Taphoorn, Medical Center Haaglanden, the Hague, and VU University Medical Center, Amsterdam, the Netherlands; Roger Henriksson, Cancer Center Stockholm Gotland, Karolinska, Stockholm, and Umeå University, Umeå, Sweden; Andrew Bottomley, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Timothy Cloughesy, University of California, Los Angeles, Los Angeles; Christina Theodore-Oklota and Arliene Ravelo, Genentech, South San Francisco, CA; Wolfgang Wick, University Hospital of Heidelberg, Heidelberg, Germany; Warren Mason, Princess Margaret Hospital, Toronto, Ontario, Canada; Frank Saran, The Royal Marsden National Health Service Foundation Trust, Surrey, United Kingdom; Ryo Nishikawa, Saitama Medical University, Saitama, Japan; Magalie Hilton, F. Hoffmann-La Roche, Basel, Switzerland; Olivier L. Chinot, Service de Neuro-Oncologie, Aix-Marseille University, Assistance Publique- Hôpitaux de Marseille, Centre Hospitalier Universitaire Timone, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.3217DOI Listing
July 2015

Bevacizumab in recurrent glioblastoma: five informative patient scenarios.

Authors:
Warren P Mason

Can J Neurol Sci 2015 May 8;42(3):149-56. Epub 2015 Apr 8.

Department of Medicine,Princess Margaret Cancer Centre and University of Toronto,Toronto,Ontario,Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/cjn.2015.21DOI Listing
May 2015

End of the road: confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastoma.

Authors:
Warren P Mason

Neuro Oncol 2015 May 13;17(5):634-5. Epub 2015 Feb 13.

Department of Medicine, Princess Margaret Cancer Centre and University of Toronto.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482863PMC
May 2015

Phase II study of PX-866 in recurrent glioblastoma.

Neuro Oncol 2015 Sep 20;17(9):1270-4. Epub 2015 Jan 20.

CancerCare Manitoba, Winnipeg, Canada (M.W.P., S.B.); Queen's University, Department of Oncology, Kingston, Canada (E.A.E.); Dalhousie University,Halifax, Canada (M.V.M.); BritishColumbia Cancer Agency, Vancouver, Canada (B.T.); Tom Baker Cancer Centre, Calgary, Canada (J.C.E.); London Regional Cancer Program, London, Canada (D.R.M.); University of Alberta, Edmonton, Canada (D.D.E.); Allan Blair Cancer Center, Regina, Canada (A.S.K., M.S., H.C.); Department of Pathology and Molecular Medicine, Queen's University, Kingston, Canada (J.S.); Department of Pathology, University Health Network, University of Toronto, Toronto, Canada (M.S.T., S.K.-R.); NCIC Clinical Trials Group, Queen's University, Kingston, Canada (D.T., J.P.); Oncothyreon, Inc., Seattle, Washington (D.F.H.); Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada (W.P.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nou365DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588751PMC
September 2015

Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group.

Neuro Oncol 2015 Feb 26;17(2):180-8. Epub 2014 Aug 26.

Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (B.M.A., L.T., K.L.L., P.Y.W.); Mayo Clinic, Rochester, Minnesota (E.G., K.V.B., B.P.O., J.N.S.); The University of Texas M.D. Anderson Cancer Center, Houston, Texas (W.K.A.Y., J.F.D., D.A.B.); St. Jude Children's Research Hospital, Memphis, Tennessee (J.M.B.); University of California, Los Angeles, California (T.F.C.); Memorial Sloan-Kettering Cancer Center, New York, New York (J.T.H., I.K.M.); National Cancer Institute, Bethesda, Maryland (B.M., A.T.-A.); Princess Margaret Cancer Centre, Toronto, Ontario, Canada (W.M.); Henry Ford Hospital, Detroit, Michigan (T.M.); University of California, San Diego, La Jolla, California (P.S.M.); University of California, San Francisco, California (M.D.P.); Johns Hopkins University, Baltimore, Maryland (X.Y.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nou154DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288520PMC
February 2015

Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.

Neuro Oncol 2015 Mar 19;17(3):430-9. Epub 2014 Aug 19.

Dana-Farber Cancer Institute, Boston, Massachusetts (D.A.R.); University of Alabama, Birmingham, Alabama (L.B.N.); Princess Margaret Hospital, Toronto, Ontario, Canada (W.P.M.); Odette Cancer Centre, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (J.R.P.); Barrow Neurological Institute, Phoenix, Arizona (W.S.); Department of Medical Oncology, McGill University, Montréal, Quebec, Canada (P.K.); Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada (D.M.); Johnnie Cochran Brain Tumor Center, Cedars-Sinai Medical Center, Los Angeles, California (S.P., A.C.); Boehringer Ingelheim R.C.V GmbH & Co KG, 1120 Vienna, Austria (A.C.); Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut (Y.F., J.C.); Boehringer Ingelheim Pharma GmbH & Co. K.G., 88400 Biberach, Germany (S.S.W.); CancerCare Manitoba, Winnipeg, Manitoba, Canada (D.D.E.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nou160DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4483093PMC
March 2015

Are patients open to elective re-sampling of their glioblastoma? A new way of assessing treatment innovations.

Acta Neurochir (Wien) 2014 Oct 2;156(10):1855-62; discussion 1862-3. Epub 2014 Aug 2.

Division of Neurosurgery, Toronto Western Hospital, University of Toronto, West Wing, 4th Floor Rm 4 W448, 399 Bathurst St., Toronto, ON, M5T2S8, Canada,

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00701-014-2189-3
Publisher Site
http://dx.doi.org/10.1007/s00701-014-2189-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167439PMC
October 2014

Emerging biomarkers in anaplastic oligodendroglioma: implications for clinical investigation and patient management.

CNS Oncol 2013 Jul;2(4):351-8

Pencer Brain Tumor Centre, Princess Margaret Cancer Center, 610 University Avenue, Toronto, ON, M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/cns.13.26DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166534PMC
July 2013

Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.

Neuro Oncol 2014 Nov 4;16(11):1541-6. Epub 2014 Jul 4.

Departments of Neurology (A.B.L., F.M.I., L.E.A., L.M.D.), Pathology (S.C.J., M.K.R.), Epidemiology & Biostatistics (A.S.R., K.S.P.), and the Brain Tumor Center, Memorial Sloan-Kettering Cancer Center, New York, New York; University of California, Los Angeles, Los Angeles, California (T.F.C.); Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas (K.D.A., A.L.R.); Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (A.F.E., D.N.L.); NorthShore University Health System, Evanston Hospital Kellogg Cancer Center, University of Chicago, Pritzker School of Medicine, Evanston, Illinois (N.A.P.); London Regional Cancer Program, London, Ontario, Canada (B.J.F.); Barrow Neurological Institute, Phoenix, Arizona (L.S.A.); University of Calgary, Calgary, Alberta, Canada (J.G.C., G.B.R.U.); Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts (P.Y.W.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Children's Hospital Boston, Brigham and Women's Hospital, Boston, Massachusetts (K.L.L.); University of Virginia Health System, Charlottesville, Virginia (D.S.); University of Wisconsin, Madison, Wisconsin (H.I.R., B.G.R.); University of Washington, Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, Seattle, Washington (M.C.C.); Princess Margaret Hospital, Toronto, Ontario, Canada (W.P.M.); Albany Medical Center, Albany, New York (S.A.W.); Kaiser Permanente-Los Angeles Medical Center, Los Angeles, California (R.M.G.); Clemenceau Medical Center, Beirut, Lebanon and Université Saint-Esprit de Kaslik, Byblos, Lebanon (F.G.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nou083DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201067PMC
November 2014

Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy?

Future Oncol 2014 May;10(7):1137-45

Department of Medical Oncology, Azienda USL Bellaria-Maggiore Hospital, Via Altura 3, Bologna, 40139, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.14.75DOI Listing
May 2014

Seizure management in patients with gliomas.

Expert Rev Neurother 2014 Apr 19;14(4):367-77. Epub 2014 Feb 19.

University Health Network, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737175.2014.890890DOI Listing
April 2014

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

N Engl J Med 2014 Feb;370(8):709-22

From Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Service de Neuro-Oncologie, Centre Hospitaliere Universitaire Timone, Marseille (O.L.C.), UFR de Santé, Médecine et Biologie Humaine, Bobigny (A.F.C.), and Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Avicenne, Service de Neurologie, Université Paris 13 (A.F.C.), and AP-HP, Université Pierre-et-Marie-Curie, Group Hospitalier Pitié-Salpêtrière (K.H.-X.), Paris - all in France; University Hospital of Heidelberg, Department of Neurooncology, and German Cancer Consortium, German Cancer Research Center, Heidelberg, Germany (W.W.); Princess Margaret Hospital, Toronto (W.M.), and McGill University, Montreal (P.K.) - both in Canada; Regional Cancer Center, Stockholm Gotland, Karolinska, Stockholm, and the Department of Radiation Sciences and Oncology, Umeå University, Umeå - both in Sweden (R.H.); the Royal Marsden National Health Service Foundation Trust, Sutton, Surrey, United Kingdom (F.S.); Saitama Medical University, Saitama, Japan (R.N.); Oncology Institute "Ion Chiricuta," Cluj-Napoca, Romania (D.C.); Medical Oncology Department, Azienda Unità Sanitaria Locale, Bologna, Italy (A.A.B.); F. Hoffmann-La Roche, Basel, Switzerland (M.H., L.A.); and University of California, Los Angeles, Los Angeles (T.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1308345DOI Listing
February 2014

Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era.

J Neurooncol 2014 Mar 29;117(1):153-60. Epub 2014 Jan 29.

Department of Medical Oncology, Pencer Brain Tumor Centre, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON, M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-014-1368-7DOI Listing
March 2014

Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies.

Lancet Neurol 2014 Mar 22;13(3):276-86. Epub 2014 Jan 22.

August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA; Hospital Clinic, University of Barcelona, Barcelona, Spain; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(13)70299-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4838043PMC
March 2014

Emerging biomarkers in glioblastoma.

Cancers (Basel) 2013 Aug 22;5(3):1103-19. Epub 2013 Aug 22.

Pencer Brain Tumor Centre, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers5031103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795381PMC
August 2013

Glioblastoma management in the temozolomide era: have we improved outcome?

J Neurooncol 2013 Nov 25;115(2):303-10. Epub 2013 Aug 25.

Princess Margaret Hospital, 610 University Avenue, Suite 18-717, Toronto, ON, M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-013-1230-3DOI Listing
November 2013

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.

J Clin Oncol 2013 Sep 12;31(26):3212-8. Epub 2013 Aug 12.

Tracy T. Batchelor, Rakesh K. Jain, and Gregory Sorensen, Massachusetts General Hospital, Boston, MA; Paul Mulholland, University College London, London; Rao Gattamaneni, the Christie Foundation Trust Hospital, Manchester, United Kingdom; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; L. Burt Nabors, University of Alabama at Birmingham, Birmingham, AL; Mario Campone, Centre Rene Gauducheau, Saint-Herblain, France; Antje Wick, University of Heidelberg, Heidelberg, Germany; Warren Mason, Princess Margaret Hospital, Toronto, Ontario, Canada; Tom Mikkelsen, Henry Ford Hospital, Detroit, MI; Surasak Phuphanich, Cedars-Sinai Medical Center, Los Angeles, CA; Lynn S. Ashby, Barrow Neurological Institute, Phoenix, AZ; John DeGroot, MD Anderson Cancer Center, Houston, TX; Lawrence Cher, Austin Health Cancer Services; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Australia; Franz Payer, Medical University, Graz, Austria; Juliane M. Jürgensmeier, John Xu, and Qi Liu, AstraZeneca, Wilmington, DE; and Martin van den Bent, Erasmus University Medical Center-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.47.2464DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021043PMC
September 2013

Anaplastic oligodendroglioma: advances and treatment options.

Curr Treat Options Neurol 2013 Jun;15(3):289-301

Pencer Brain Tumor Centre, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario, M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11940-013-0218-9
Publisher Site
http://dx.doi.org/10.1007/s11940-013-0218-9DOI Listing
June 2013

Management of glioblastoma in the elderly.

Clin Adv Hematol Oncol 2012 Jun;10(6):379-86

Princess Margaret Hospital, University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
June 2012

Antiangiogenic therapies in glioblastoma multiforme.

Expert Rev Anticancer Ther 2012 May;12(5):643-54

Pencer Brain Tumor Centre, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.12.35DOI Listing
May 2012

Long-term outcomes for adult craniopharyngioma following radiation therapy.

Acta Oncol 2013 Jan 8;52(1):153-8. Epub 2012 May 8.

Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/0284186X.2012.685525DOI Listing
January 2013

Anaplastic astrocytomas.

Handb Clin Neurol 2012 ;105:451-66

Department of Medicine, University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-444-53502-3.00002-1DOI Listing
April 2012

A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression.

J Neurooncol 2012 Apr 3;107(2):343-9. Epub 2011 Nov 3.

Princess Margaret Hospital, 610 University Avenue, Suite 18-717, Toronto, ON, M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-011-0747-6DOI Listing
April 2012

Right frontal lobe mediation of recollection- and familiarity-based verbal recognition memory: evidence from patients with tumor resections.

J Cogn Neurosci 2011 Dec 12;23(12):3804-16. Epub 2011 May 12.

Rotman Research Institute, Baycrest, 3560 Bathurst Street, Toronto, ON M6A 2E1 Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1162/jocn_a_00050DOI Listing
December 2011

Upfront observation versus radiation for adult pilocytic astrocytoma.

Cancer 2011 Sep 9;117(17):4070-9. Epub 2011 Mar 9.

Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25988DOI Listing
September 2011

Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas.

Core Evid 2010 Jun 15;4:93-111. Epub 2010 Jun 15.

Department of Medicine, Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada;

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2899776PMC
http://dx.doi.org/10.2147/ce.s6010DOI Listing
June 2010

Leptomeningeal gliomatosis as the initial presentation of gliomatosis cerebri.

J Neurooncol 2010 Oct 10;100(1):145-9. Epub 2010 Feb 10.

Faculty of Medicine, UME Office, Health Sciences Centre, University of Calgary, 3330 Hospital Dr. NW, Calgary, AB, T2N 4N1, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-010-0138-4DOI Listing
October 2010

Low-grade oligodendroglioma: current treatments and future hopes.

Expert Rev Anticancer Ther 2009 Nov;9(11):1651-61

Room 7-702, Princess Margaret Hospital, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.09.127DOI Listing
November 2009

Management of malignant melanoma: best practices.

J Cutan Med Surg 2009 Mar-Apr;13(2):55-73

Cross Cancer Institute, Edmonton, AB, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2310/7750.2008.08029DOI Listing
July 2009

Use of temozolomide in aggressive pituitary tumors: case report.

Neurosurgery 2009 Apr;64(4):E773-4; discussion E774

Division of Neurosurgery, St. Michael's Hospital, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1227/01.NEU.0000339115.12803.4EDOI Listing
April 2009

A novel tool to analyze MRI recurrence patterns in glioblastoma.

Neuro Oncol 2008 Dec 31;10(6):1019-24. Epub 2008 Jul 31.

Department of Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1215/15228517-2008-058DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2718999PMC
December 2008

Invited article: the expanding impact of molecular biology on the diagnosis and treatment of gliomas.

Neurology 2008 Jul;71(5):365-73

Department of Medicine, the University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/01.wnl.0000319721.98502.1bDOI Listing
July 2008

Patients' perception of the informed consent process for neurooncology clinical trials.

Neuro Oncol 2008 Jun 3;10(3):348-54. Epub 2008 Apr 3.

Division of Neurosurgery, Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1215/15228517-2008-007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2563057PMC
June 2008

Emerging drugs for malignant glioma.

Authors:
Warren P Mason

Expert Opin Emerg Drugs 2008 Mar;13(1):81-94

Princess Margaret Hospital, Department of Medicine, 610 University Avenue, Suite 18-717, Toronto, Ontario, M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728214.13.1.81DOI Listing
March 2008